SEC Form 4 · accession 0001171780-26-000012
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward J Rapp
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001551152
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Equivalent UnitsF2,F1 | $251.64 | Jun 30, 2026 | A | 134 | A | — | — | Common Stock | 134 | 29,236 | D |
Explanation of responses
- F1Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
- F2Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.